Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not known whether giving interleukin-2 with surgery and radiation therapy is more effective than surgery and radiation therapy alone.
PURPOSE: This randomized phase III trial is studying surgery and radiation therapy alone to see how well they work compared to surgery, radiation therapy, and interleukin-2 in treating patients with cancer of the mouth or oropharynx.
研究概览
详细说明
OBJECTIVES:
- Compare the disease-free and overall survival in patients with previously untreated squamous cell carcinoma of the oral cavity or oropharynx treated with resection with or without and neoadjuvant and adjuvant perilymphatic interleukin-2 (IL-2) and radiotherapy.
- Compare the response rate in patients treated with these regimens.
- Determine the local and systemic effects of locoregional IL-2 on host-tumor interaction and immune properties in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center and tumor stage (T2, N0-2 vs T2, N3 or T3-4, N0-3). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo induction comprising interleukin-2 (IL-2) via perilymphatic injections to the ipsilateral myelohyoid muscle and insertion of the sternocleidomastoid muscle on days 1-5 and 8-12. Within 10 days after the last IL-2 injection, patients undergo en bloc resection of the primary tumor and corresponding lymphatic drainage area and pre-study margins. Beginning within 4 weeks after surgery, patients with T2, N0-3 disease but with pathohistological evidence of node invasion or capsular rupture of node metastasis or T3-4, N0-3 disease undergo adjuvant radiotherapy 5 days a week for 4.5-6.5 weeks. Beginning within 4 weeks after surgery or radiotherapy (if applicable), patients receive adjuvant IL-2 via perilymphatic injections to the contralateral myelohyoid muscle and insertion of the sternocleidomastoid muscle on days 1-5. Adjuvant IL-2 continues monthly for at least 1 year in the absence of disease progression.
- Arm II: Patients undergo resection and radiotherapy (if eligible) as in arm I. Patients are followed monthly for 1 year and then every 2 months for 2 years.
PROJECTED ACCRUAL: A total of 260 patients (130 per treatment arm) will be accrued for this study.
研究类型
注册 (预期的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Bari、意大利、70124
- 招聘中
- Università degli Studi di Bari
-
接触:
- G. Cervellera, MD
- 电话号码:39-080-5478-660
-
Cagliari、意大利、09042
- 招聘中
- Cattedra di Oncologia Medica - Universita degli Studi di Cagliari
-
接触:
- P. Puxeddu, MD
- 电话号码:39-070-5109-6253
-
Ferrara、意大利、44100
- 招聘中
- Università di Ferrara
-
接触:
- C. Calearo, MD
- 电话号码:39-0532-209-296
- 邮箱:ccv@dns.unife.it
-
Florence、意大利、50134
- 招聘中
- Universita Degli Studi di Florence - Policlinico di Careggi
-
接触:
- O. Fini-Storchi, MD
- 电话号码:39-55-411739
-
Turin、意大利、10126
- 招聘中
- Universita Di Torino
-
接触:
- G. Valente, MD
- 电话号码:39-011-670-5955
-
Turin、意大利、10128
- 招聘中
- Azienda Sanitaria Ospedaliera Ordine Mauriziano
-
接触:
- G. Forni, MD
- 电话号码:39-11-508-1111
-
Vicenza、意大利、36100
- 招聘中
- Ospedale San Bortolo
-
接触:
- C. Curioni, MD
- 电话号码:39-444-993-906
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Histologically proven squamous cell carcinoma of the oral cavity or oropharynx
- Operable, primary, unilateral, stage T2-4, N0-3, M0 disease
- No high probability of bilateral lymphatic spread (requirement for bilateral neck dissection)
No tumor involvement of the following sites:
- Pterygopalatine fossa
- Carotid artery
- Maxillary sinus
- Facial skin
- Anterior floor of the mouth
- Base of the tongue infiltrating more than 1 cm
- Measurable or evaluable disease by physical exam and/or noninvasive imaging
PATIENT CHARACTERISTICS:
Age:
- 75 and under
Performance status:
- ECOG 0-2 OR
- Karnofsky 70-100%
Life expectancy:
- More than 3 months
Hematopoietic:
- WBC at least 4,000/mm3
- Platelet count at least 60,000/mm3
- Hematocrit at least 30%
Hepatic:
- Bilirubin normal
- Hepatitis B surface antigen negative
Renal:
- Creatinine normal
Cardiovascular:
- No congestive heart failure
- No uncontrolled hypertension
- No coronary artery disease
- No serious arrhythmia
- No evidence of prior myocardial infarction on ECG (stress test required if in doubt)
Other:
- HIV negative
- No autoimmune disease
- No contraindications to pressor agents
- No serious infection requiring antibiotics
- No other concurrent primary malignancy
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior or other concurrent immunotherapy
Chemotherapy:
- No prior or concurrent chemotherapy
Endocrine therapy:
- No prior or concurrent hormonal therapy
- No concurrent corticosteroids
Radiotherapy:
- No prior radiotherapy
Surgery:
- See Disease Characteristics
- No prior major organ allografts
Other:
- No other prior therapy
- No other concurrent investigational drugs, agents, or devices
- No concurrent nonsteroidal antiinflammatory drugs, ranitidine, cimetidine, or coumarin
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
研究衡量的是什么?
主要结果指标
结果测量 |
---|
反应速度
|
Disease-free survival at 3 and 5 years
|
Recurrence/metastasis rate at 3 and 5 years
|
Local and systemic effects of treatment
|
合作者和调查者
调查人员
- 学习椅:Giorgio Cortesina, MD、Universita Degli Studi di Turin
研究记录日期
研究主要日期
学习开始
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CDR0000064500
- CNR-9506
- EU-95024
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
阿地白介素的临床试验
-
Groupe Francophone des MyelodysplasiesEpiCept Corporation撤销
-
University Health Network, Toronto完全的
-
University Health Network, Toronto主动,不招人
-
University Health Network, TorontoMerck Sharp & Dohme LLC完全的